Promising Clinical Trial Data for Migraine Treatment: CER-0001, a Ketogenic Investigational Agent

03 July 2023 | Monday | News

Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, presented encouraging findings from a recent study on CER-0001 (tricaprilin), an investigational ketogenic agent, indicating that certain individuals suffering from migraines may experience benefit.
Image Source : Public Domain

Image Source : Public Domain

  • A poster showcasing data from the RELIEF study of CER-0001 (tricaprilin), being investigated for the preventive treatment of migraine, was presented at the 65th Annual Society Meeting of the American Headache Society
  • Data from the pilot study, showed a positive efficacy signal and supports advancement of CER-0001 into pivotal studies
  • The poster was presented by Cerecin's Chief Medical Officer, Dr Marc Cantillon

 The data will be used to inform future studies. The study's findings were highlighted in a poster presentation at the 65th Annual Society Meeting of the American Headache Society, held in Austin, Texas from June 15-18, 2023. The poster was presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon. The poster was entitled, Metabolic Mechanism in Migraine: Tricaprilin, a Ketogenic Agent.


The RELIEF study was a double-blind, randomized, placebo-controlled, 3-month study of up to 60 g/day tricaprilin. The primary endpoint was the change from baseline in the number of migraine headache days (MHDs) during month three. Eligible participants had 4-24 MHDs in the baseline period. The study was registered on (NCT04437199). The primary endpoint was not met due to lack of statistical power, however, an efficacy signal was noted in sensitivity analyses. Some patients opted to enter the CER-0001 Compassionate Access Program which provides continued access to CER-0001 (tricaprilin) for up to one year after completion of the clinical study.

Given that metabolic factors have been implicated in migraine etiology, the induction of ketosis via ketogenic drugs like tricaprilin could potentially offer an innovative approach to managing this condition. Professor Mark Bloch, Associate Professor at University of New South WalesSydney and RELIEF study investigator commented, "It is important that the headache field is aware of development of novel mechanism drugs, such as tricaprilin. This metabolism-based option is promising and should continue in development as a possible future treatment option."

The RELIEF study's preliminary findings support the further study of the investigational drug tricaprilin as a preventive treatment for migraines and affirm Cerecin's commitment to exploring cutting-edge therapeutics in the field of neurology.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in